Gland Pharma reports Revenue of Rs 56,165 Mn for FY25 With improved Gross Profit Margin

India Pharma Outlook Team | Wednesday, 21 May 2025

 Gland Pharma reports Revenue of Rs 56,165 Mn for FY25 With improved Gross Profit Margin

Gland Pharma Limited (BSE: 543245 I NSE: GLAND), a generic injectable-focused pharmaceutical company, today announced its financial results for the fourth quarter and year ended on March 31st, 2025.

Commenting on the results, Mr. Srinivas Sadu, Executive Chairman of Gland Pharma, said, “FY25 was a year of strategic realignment and investment in future growth. Through the year we mitigated many challenges and strengthened the core by advancing key pillars of manufacturing, quality, and R&D. Our approach involves expanding our core business into new emerging markets, carefully enhancing our manufacturing capabilities to encompass complex injectables and novel delivery systems and building pipeline through our robust in-house research and development efforts. Our progress in biologics CDMO and collaborations with leading partners reflect our intent to diversify and grow beyond traditional segments. We remain firmly focused on executing the Cenexi turnaround and leveraging targeted M&A to drive long-term, sustainable value for all stakeholders.”

 Commenting on the results, Mr. Shyamakant Giri, Chief Executive Officer of Gland Pharma, said, “In Q4 FY25 our consolidated revenue reached INR 14,249 million, with a healthy EBITDA margin of 24%. On the base business the EBITDA margin expanded to 38%, driven by volume traction in our U.S. portfolio and high-margin new product launches. Cenexi posted modest sequential improvement in revenue & gross margin and we remain firmly committed to its turnaround. Looking ahead, our strategic focus is on accelerating growth in RoW and India, deepening our U.S. presence through portfolio enhancement, and continuing to lead on quality and cost efficiency.”

Source: Press Release

© 2025 India Pharma Outlook. All Rights Reserved.